AstraZeneca's Imfinzi gained FDA approval as the first immunotherapy for muscle-invasive bladder cancer, showing a 32% lower recurrence risk and 25% lower death risk compared to chemotherapy.
AstraZeneca's Calquence has gained a positive nod from the European Medicines Agency for first-line treatment of untreated mantle cell lymphoma, showing a 27% lower risk of disease progression.
AstraZeneca's AZD0780 cut LDL cholesterol by 50.7% in a phase 2b trial. 84% of those on AZD0780 met LDL-C targets, with similar safety profiles to placebo.
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.